Celgene’s Otezla impresses at Phase 3 in scalp psoriasis

pharmafile | October 9, 2018 | News story | Manufacturing and Production, Research and Development Celgene, pharma, psoriasis 

Celgene has unveiled new Phase 3 data for Otezla (apremilast), its inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP), in the treatment of moderate to severe scalp psoriasis, with users showing a “highly statistically significant” increase in Scalp Physician’s Global Assessment (ScPGA) response, achieving its primary endpoint.

Specifically, patients taking 30mg twice daily reported a ScPGA response of 0 or 1, representing clear or almost clear respectively, with at least a two-point reduction from baseline after 16 weeks, compared to placebo.

Over the same period, the second endpoint of the study reached statistical significance, represented by at least a four-point reduction on the whole body itching numeric rating scale (NRS) versus placebo.

“The scalp is the most commonly affected area in moderate to severe plaque psoriasis, impacting up to 80% of patients,” commented Terrie Curran, President of Celgene Inflammation and Immunology. “The area is difficult to treat with topical therapies, and clinical data from systemic therapies are limited. We are encouraged by the significant improvements in this trial and look forward to sharing these data to further enhance the Otezla label.”

Matt Fellows

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

Latest content